Lifting the ‘Breakthrough’ Veil: FDA Increases Transparency To Reduce Futile Requests

Case studies demonstrating what kinds of drugs do and don’t qualify for the expedited pathway designation will be presented at an April workshop co-sponsored by the Brookings Institution.